{
    "title": "Pfizer looks beyond COVID after quarterly loss on Paxlovid charge",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-12692635/Pfizer-swings-quarterly-loss-Paxlovid-write-off.html",
    "date": "2023-10-31",
    "keywords": [
        "vaccine",
        "pfizer",
        "year",
        "revenue",
        "growth",
        "loss",
        "paxlovid",
        "quarter",
        "company",
        "share",
        "bhanvi",
        "satija",
        "michael",
        "rsv",
        "abrysvo",
        "demand",
        "month",
        "government",
        "treatment",
        "bourla",
        "virus",
        "influenza",
        "end",
        "tuesday",
        "drugmaker",
        "charge",
        "inventory",
        "decline",
        "use",
        "covid",
        "pandemic",
        "drop",
        "drag",
        "midday",
        "trading",
        "pressure",
        "guidance",
        "capital",
        "analyst",
        "partner",
        "biontech",
        "record",
        "vaccination",
        "immunity",
        "call",
        "majority",
        "half",
        "portfolio",
        "respiratory",
        "launch",
        "officer",
        "hwang",
        "shot",
        "gsk",
        "pharmacy",
        "chain",
        "update",
        "messengerrna",
        "flu",
        "latestage",
        "study",
        "midstage",
        "obesity",
        "pill",
        "danuglipron",
        "industrys",
        "market",
        "deal",
        "cancertherapy",
        "specialist",
        "seagen",
        "europe",
        "program",
        "profit",
        "reporting",
        "khushi",
        "mandowara",
        "bengaluru",
        "erman",
        "york",
        "editing",
        "kalluvila",
        "bill",
        "berkrot"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}